Amoéba, an industrial greentech specialising in the development of natural microbiological solutions based on the patented use of amoebae, announces that the US Environmental Protection Agency (US EPA) has confirmed the admissibility and completeness of the registration dossier for its biocontrol products in the United States.

Amoéba , an industrial greentech specialising in the treatment of microbiological risk, announces a major legal reorganisation designed to strengthen the development of its commercial activities in the biocontrol and cosmetics sectors, and to create value for its shareholders.

Amoeba, an industrial greentech specialised in the treatment of microbiological risk, developing a biocontrol agent for the protection of plants in agriculture and a range of cosmetic ingredients, announces that it has received the results of the clinical study confirming the interest of using its ingredient in cosmetic as a skin care product.

Amoéba, an industrial biotech specialised in the treatment of microbiological risk, developing a biocontrol agent for the protection of plants in agriculture and a range of anti-ageing cosmetic ingredients, is appointing a new Board of Directors, welcoming four well-known figures specialised in the fields that represent the company’s core activities.

Amoéba announces additional information following a change in governance, and a review of the company’s growth focus.

Amoéba announces additional information following a change in governance, and a review of the company’s growth focus.

Amoéba today announced a strengthening of governance and commercial strategy and the deferral of the industrial project

Amoéba announces the publication of its 2023 test results, a campaign year that allows the refining of AXPERA’s commercial strategy.

Amoéba announces the publication of a third peer-reviewed scientific article in Plants, presenting the efficacy of Amoéba’s biocontrol products on tomato late blight and powdery mildews of tomato.

Amoéba announces that it has obtained convincing results for the use of Willaertia magna C2c Maky lysate in cosmetic skin care and has filed a patent application for this invention.

Amoéba announces the start of work on the USIBIAM industrial project in Cavaillon on schedule.

Amoéba announces reporting its earnings for the first half of 2023

Amoéba confirms that the regulatory timetable for the biocontrol active substance application is in line with the Company’s forecasts.

Amoéba announces today the brand name of its biocontrol solutions, with a view to commercialization expected in early 2025.

Amoéba announces today that Portzamparc – BNP Paribas Group has initiated coverage on the company.

Amoéba informs that the notice of the meeting as a notice of convocation, including the agenda and the planned resolutions, was published in the BALO (Bulletin of obligatory legal announcements) of 19 april, 2023.

Amoéba announces that the 2022 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers-AMF) on April 18, 2023

Amoéba announces that Nissan Chemical Corporation has started a performance evaluation study of the mixture of one of its products with an Amoéba biocontrol experimental product.

Amoéba today announces its annual results for the year ending 31 December 2022.

Amoéba announces the support of BPI France in the framework of the national financing plan “France 2030”.

Amoéba announces that Edison Group, a London-based equity research house, has initiated coverage on the company.

Amoéba announces that it has applied for building permit for its new production site dedicated to biocontrol application, based in Cavaillon in the south of France.

Amoéba announces the signature of a new simple bond financing agreement of 9 million euros with the Swiss company Nice & Green SA.

Amoéba announces that it has terminated its convertible bond issue contract with Nice & Green SA and waived the issue of the 8th optional tranche of 80 OCAs. In order to adapt its financial strategy to its new industrial transformation challenges, Amoéba has concluded a contract with Redbridge Debt and Treasury Advisory to assist it in its search for financing.

Amoéba informs that the US Environmental Protection Agency (US EPA) has approved the use of the Willaertia magna C2c Maky as an active substance for use cooling systems.

Amoéba announces that the US EPA has approved the use of the lysate of Willaertia magna C2c Maky as an active substance for use in plant protection.

Amoéba announces the publication of its 2022 field trial results, a record year for the number and performance of field trials.

Amoéba announces that it will not pursue the application for its living amoeba-based biocide in Canada.

Amoéba announces the publication of a scientific article concerning the efficacy of its biocontrol products to fight potato late blight.

Amoéba informs that the US EPA approves tolerance exemption for the biocontrol active substance on foodstuffs.

Amoéba announces today that it has published its Interim Financial Report for 2022.

Amoeba announces its half-year results for 2022

Amoéba informs that the United States Environmental Protection Agency (US EPA) has made a positive pre-decisional determination following its assessment of the application dossier for the use of the Lysate of Willaertia magna C2c Maky as a biocontrol active ingredient (biopesticide) in agriculture.

Amoéba announces the issuance of the sixth tranche of 60 bonds convertible into shares.

Amoéba informs that the US EPA has made a positive pre-decisional determination for the use of Amoéba’s biocide in closed cooling systems.

Amoéba announces the issuance of the fifth tranche of 60 bonds convertible into shares as part of its new bond financing with incentive program with Nice & Green S.A.

Amoeba announces that the US EPA, in charge of the evaluation of the biocide and biocontrol applications in the United States, has requested an extension of the assessment period : the conclusions should now be available in the second half of 2022.

Amoéba announces the availability of preparatory documents for the General Assembly of May 24, 2022

Amoeba announces that the Maltese authority recommends the non-approval of the biocidal active substance for the European territory

Amoéba announces that AGES, in charge of the application for approval of the biocontrol active substance “Lysate of Willaertia magna C2c Maky”, recommends its approval for use in plant protection on the European territory.

Amoéba announces that the 2021 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers AMF) on April 12, 2022.

Amoéba announces having exercised the suspension option relating to the issuance of the 5th tranche of OCAs, initially scheduled for April 5, 2022.

Amoéba announces a report of the conclusion of the evaluation of the European biocide and biocontrol dossiers.

Amoeba confirms its biocontrol’s effectiveness against major cereal diseases

Amoéba announces the results of the field trials 3rd campaign on grapes

Malta commits to finalize the report in the 4th quarter of 2021

Philippe Dujardin replaces Pascal Reber as independent director

Availability of the preparatory documents for the General meeting of 27 may 2021

Amoéba provides shareholders with preparatory documents

Amoeba continues testing its biocontrol product in 2021

Amoéba extends to the U.S.A. the testing of its biocontrol

Amoéba has appointed Pierre Morgon as censor.

Signature of a Letter of Intent (LOI) with PHILAGRO France

in Switzerland with Stähler for its vine Bioncontrol product.